[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Chacko Jacob, President and CEO and a director of Oric Pharmaceuticals, sold 125,000 shares of the company's common stock on September 22, 2025 under a Rule 10b5-1 trading plan. The reported weighted average price for the aggregate sale was $10.7995, with the shares sold in a range of $10.57 to $10.92. After the sale, the reporting person beneficially owned 656,419 shares of common stock directly. The filing also discloses outstanding equity awards not included in that total: 178,667 RSUs and stock options to purchase 3,378,000 shares, which were previously reported on Table II.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating pre-arranged trading and reduced appearance of opportunistic timing
• Clear disclosure of weighted average sale price ($10.7995) and price range ($10.57–$10.92)
• Separation of holdings—directly owned shares are reported separately from RSUs and stock options, improving transparency

Negative

• Significant insider sale of 125,000 shares reported, which reduces the reporting person's direct holdings to 656,419 shares
• Large outstanding derivative positions remain: 178,667 RSUs and options for 3,378,000 shares, which could be dilutive when exercised or settled

Insights

Securities Analyst

TL;DR: Insider sale executed under a pre-established 10b5-1 plan; disclosure is routine and provides liquidity rather than new information.

The sale of 125,000 shares was effected pursuant to a Rule 10b5-1 plan adopted June 21, 2025, which indicates the transactions were pre-arranged and not opportunistic trades tied to undisclosed material information. The reporting of the weighted average price ($10.7995) and the price range ($10.57–$10.92) provides transparency on execution. Material additional holdings include 178,667 RSUs and options for 3,378,000 shares; these outstanding derivative positions are significant in aggregate but were previously reported. Overall, this Form 4 is a standard insider liquidity event with clear documentation.

Corporate Governance Expert

TL;DR: Sale follows corporate governance best practices by using a 10b5-1 plan and timely SEC disclosure.

The filing shows compliant behavior: use of a 10b5-1 plan adopted on June 21, 2025, and a signed Form 4 filed September 24, 2025. The report explicitly separates currently owned common stock from contingent RSUs and previously reported options, improving clarity for stakeholders. While insider sales can raise investor questions, the documented use of a pre-established plan and full disclosure align with governance standards for executive transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Chacko Jacob

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		S(1)		125,000	D	$10.7995(2)	656,419(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

2. Represents the weighted average share price of an aggregate total of 125,000 shares sold in the price range of $10.57 to $10.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Includes 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

4. The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.

	/s/ Christian Kuhlen, attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ORIC insider Chacko Jacob report on Form 4?

The Form 4 reports that Chacko Jacob sold 125,000 shares of Oric Pharmaceuticals common stock on September 22, 2025 under a Rule 10b5-1 plan.

At what price were the ORIC shares sold?

The aggregate weighted average sale price was reported as $10.7995, with sales occurring in the price range of $10.57 to $10.92.

How many ORIC shares does Chacko Jacob beneficially own after the sale?

After the reported transaction, the filing shows 656,419 shares of ORIC common stock beneficially owned directly by the reporting person.

Does the filing disclose other equity interests held by Chacko Jacob?

Yes. The filing states the reporting person holds 178,667 RSUs and stock options to purchase 3,378,000 shares, which were previously reported on Table II and are not included in the direct ownership total.

Was the sale part of a pre-established trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted June 21, 2025, as disclosed in the Form 4.